Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) have earned an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the last year […]